Stemtech Stock Current Liabilities
| STEK Stock | USD 0.0009 0.0001 10.00% |
Stemtech's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Stemtech OTC Stock price.
Stemtech |
Stemtech OTC Stock Current Liabilities Analysis
Stemtech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Stemtech has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Stemtech Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stemtech's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Stemtech could also be used in its relative valuation, which is a method of valuing Stemtech by comparing valuation metrics of similar companies.Stemtech is currently under evaluation in current liabilities category among its peers.
Stemtech Fundamentals
| Return On Asset | -0.75 | |||
| Profit Margin | (1.85) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 8.79 M | |||
| Shares Outstanding | 48.63 M | |||
| Shares Owned By Insiders | 63.60 % | |||
| Price To Sales | 1.54 X | |||
| Revenue | 4.32 M | |||
| Gross Profit | 3.3 M | |||
| EBITDA | 1.58 M | |||
| Net Income | (7.08 M) | |||
| Cash And Equivalents | 399.73 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 219.47 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (1.91 M) | |||
| Earnings Per Share | 0.10 X | |||
| Market Capitalization | 6.52 M | |||
| Total Asset | 5.72 M | |||
| Z Score | 17.4 | |||
| Net Asset | 5.72 M |
About Stemtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stemtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stemtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stemtech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.